Zoetis (ZTS) Stock Could Be 15.3% Undervalued After Class Action Lawsuits

Zoetis (ZTS) is back in focus after a series of securities class action lawsuits accused the company of misleading investors about weakening demand, safety concerns, and market share losses in its key companion animal products.

See our latest analysis for Zoetis.

At a share price of $78.71, Zoetis has seen pressure build over the past few months, with a 90 day share price return that declined 31.95% and a 1 year total shareholder return that declined 49.14%. Repeated class action announcements and concerns around key companion animal products have weighed on sentiment.

If this kind of legal and competitive reset has you reassessing where to put fresh capital, it can be useful to compare Zoetis with other healthcare focused opportunities using our screener for 40 healthcare AI stocks

With Zoetis stock down sharply over 1 year and trading at $78.71, investors are left weighing whether legal and competitive setbacks are already reflected in the price or if the market still expects stronger growth ahead and is not fully discounting the risks.

Most Popular Narrative: 15.3% Undervalued

Zoetis is trading at $78.71, while the most followed narrative on Simply Wall St, according to ValueInvestingSubstack, points to a fair value of $92.92 using a 7.1% discount rate. That gap has caught the attention of investors wondering if the recent legal headlines and share price decline have pushed the stock too far.

The company was spun off from Pfizer in 2013 as the “animal pharma” division, and basically makes medicines for pets and livestock. The pet division, which they call the “Companion Animal” segment, does about $6.5B in revenues, with most of it coming from Dogs and Cats. The livestock segment drew in about $2.7B in revenues in FY25, with about half of it coming from Cattle. Think of allergies or diabetes in pets, serious illnesses which warrant pharmaceutical treatment and an expense that households are willing to spend on a “family member”. That is what Zoetis addresses in a nutshell together with its army of veterinarian clinics across the world.

Read the complete narrative.

The narrative leans heavily on a broad global pet and livestock footprint, steady revenue expansion, and profitability assumptions that feed into that fair value. Curious how those revenue mix details, margin expectations, and a future earnings multiple all combine to justify a valuation above today’s price? The full narrative lays out the exact numbers behind that story.

Result: Fair Value of $92.92 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Zoetis still faces pressure from weakening US Companion Animal demand and legal actions over alleged misstatements, either of which could reshape how investors view that undervaluation story.

Find out about the key risks to this Zoetis narrative.

Next Steps

If sentiment around Zoetis feels mixed to you right now, that is exactly why it is worth moving quickly and weighing both sides of the story yourself, starting with the 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Zoetis?

If Zoetis has prompted you to reassess your watchlist, use this moment to refresh your wider opportunities list before the next round of headlines moves the market.

• Spot potential value plays early by scanning 45 high quality undervalued stocks that combine solid fundamentals with room for re rating.
• Prioritise resilience by reviewing 66 resilient stocks with low risk scores that may offer more defensive profiles when conditions become unpredictable.
• Hunt for lesser known opportunities by filtering through our screener containing 19 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com